Torasemide clinical pharmacology: pharmacokinetics and pharmacogenetics

Cover Page

Cite item

Full Text

Abstract

The article discusses the issues of pharmacogenetics in hypertensive patients, the influence of pharmacogenetic polymorphisms of different genes in the efficacy and safety of loop diuretic torasemide. A review of the scientific evidence on the influence of genetic polymorphism of metabolizing enzyme CYP2C9 and anion transporter on the pharmacokinetics of the drug (hepatic and renal clearance) and the pharmacodynamics (pronounced diuretic and salureticheskim effects) are also discussed.

About the authors

M. V Leonova

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

Email: anti23@mail.ru
чл.-кор. РАН, д-р мед. наук, проф., проф. каф. клинической фармакологии ФГБОУ ВО РНИМУ им. Н.И.Пирогова 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1

E. E Alimova

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

канд. мед. наук, доц. каф. клинической фармакологии ФГБОУ ВО РНИМУ им. Н.И.Пирогова 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1

Yu. N Eremina

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

канд. мед. наук, доц. каф. клинической фармакологии ФГБОУ ВО РНИМУ им. Н.И.Пирогова 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1

References

  1. Arnett D.K, Claas S.A, Glasser S.P. Pharmacogenetics of antihypertensive treatment. Vascul Pharmacol 2006; 44 (2): 107-18.
  2. Schelleman H, Stricker B.H, De Boer A et al. Drug - gene interactions between genetic polymorphisms and antihypertensive therapy. Drugs 2004; 64 (16): 1801-16.
  3. Polimanti R, Iorio A, Piacentini S et al. Human pharmacogenomic variation of antihypertensive drugs: from population genetics to personalized medicine. Pharmacogenomics 2014; 15 (2): 157-67.
  4. Torrellas C, Carril J.C, Cacabelos R. Benefits of Pharmacogenetics in the Management of Hypertension. J Pharmacogenomics Pharmacoproteomics 2014; 5: 1-7.
  5. Collins R, Peto R, Mac Mahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2: Short - term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38.
  6. Law M.R, Morris J.K, Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta - analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
  7. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events. A systematic review. Stroke 2003; 34: 2741-9.
  8. Psaty B.M, Lumley T, Furberg C.D et al. Health outcomes associated with various antihypertensive therapies used as first - line agents: a network meta - analysis. JAMA 2003; 289: 2534-44.
  9. Wright J.M, Musini V.M. First - line drugs for hypertension. Cohrane Database Syst Rev 2009; 8 (3): CD001841.
  10. Xue H, Lu Z, Tang W.L et al. First - line drugs inhibiting the renin angiotensin system versus other first - line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev.
  11. Mancia G, Fagard R et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-357.
  12. Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр), 2010.
  13. Kent S.T, Shimbo D, Huang L et al. Antihypertensive medication classes used among medicare beneficiaries initiating treatment in 2007-2010. PLoS ONE 9 (8): e105888.
  14. Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther 1993; 7 (Suppl. 1): 63-8.
  15. Friedel H.A, Buckley M.M. Torasemide. A review of its pharmacological properties and therapeutic potential. Drugs 1991; 41 (1): 81-103.
  16. Dunn C.J, Fitton A, Brogden R.N. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs 1995; 49: 121-42.
  17. Uchida T, Yamanaga K, Nishikawa M et al. Anti - aldosteronergic effect of torasemide. Eur J Pharmacol 1991; 205: 145-50.
  18. Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc.Drugs Ther 1993; 7 (Suppl. 1): 63-8.
  19. Luft F.C. Torasemide in the treatment of arterial hypertension. J Cardiovasc Pharmacol 1993; 22 (Suppl. 3): S32-S39.
  20. Castañeda-Hernández G, Caillé G, du Souich P. Influence of drug formulation on drug concentration - effect relationships. Clin Pharmacokinet 1994; 26 (2): 135-43.
  21. Spahn H, Knauf H, Mutschler E. Pharmacokinetics of torasemide and its metabolites in healthy controls and in chronic renal failure. Eur J Clin Pharmacol 1990; 39: 345-8.
  22. Gehr T.W, Rudy D.W, Matzke G.R et al. The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin Pharmacol Ther 1994; 56: 31-8.
  23. Schwartz S, Brater D.C, Pound D et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis. Clin Pharmacol Ther 1993; 54: 90-7.
  24. Miners J.O, Rees D.L, Valente L et al. Human hepatic cytochrome P450 2C9 catalyzes the rate - limiting pathway of torsemide metabolism. J Pharmacol Exp Ther 1995; 272: 1076-81.
  25. Miners J.O, Coulter S, Birkett D.J et al. Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes. Pharmacogenetics 2000; 10: 267-70.
  26. Lee C.R, Goldstein J.A, Pieper J.A. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in - vitro and human data. Pharmacogenetics 2002; 12: 251-63.
  27. Werner D, Werner U, Meybaum A et al. Determinants of steady - state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. Clin Pharmacokinet 2008; 47 (5): 323-32.
  28. Vormfelde S.V, Schirmer M, Hagos Y et al. Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters. Br J Clin Pharmacol 2006; 62 (3): 323-35.
  29. Burckhardt G. Drug transport by Organic Anion Transporters (OATs). Pharmacol Ther 2012; 136 (1): 106-30.
  30. Hasannejad H, Takeda M, Taki K et al. Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther 2004; 308: 1021-9.
  31. Vormfelde S.V, Schirmer M, Hagos Y et al. Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters. Br J Clin Pharmacol 2006; 62: 323-35.
  32. Vormfelde S.V, Toliat M.R, Schirmer M et al. The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 83 (6): 815-7.
  33. Vormfelde S.V, Engelhardt S, Zirk A et al. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. Clin Pharmacol Ther 2004; 76: 557-66.

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies